SynthesisPacing and clinical electrophysiology : PACE2025
Atrial Arrhythmias in Cardiac Sarcoidosis-Case Presentation and Systematic Review.
Synthesis in Pacing and clinical electrophysiology : PACE, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Atrial Arrhythmias in Cardiac Sarcoidosis-Case Presentation and Systematic Review.Pacing and clinical electrophysiology : PACE · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is a rare idiopathic, multiorgan disease with clinical cardiac involvement in approximately 5% of cases. Diagnosis and management of cardiac sarcoidosis (CS) have mainly focused on impaired LV function, ventricular arrhythmias, and atrio-ventricular conduction disease. Atrial arrhythmias (AA) may be an under-recognized manifestation of sarcoidosis, and the purpose of the study was to perform a systematic review of the current literature, with an emphasis on the prevalence and management of AA in CS. AA occur as a result of direct infiltration of granulomatous disease in the atria or secondary to atrial myopathic changes from pulmonary or ventricular disease. Positron emission tomography (PET) is the modality of choice for surveillance of disease activity in the atria. AA occur frequently, in up to 40% in patients with CS, and may be associated with frequent hospitalization and reduction in quality of life. Moreover, AA may be the predominant cardiac manifestation, and there should be some consideration to include AA as part of future iterations of the diagnostic criteria for CS. Contemporary treatment involves a combination of immunosuppression, anti-arrhythmic therapy, and catheter ablation, but recurrence occurs more frequently than in patients with non-CS AA. Further systematic studies, likely in the form of multi-center observational cohort studies, are required to inform guidelines on the specific management of AA in CS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.